Articles

CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented by New York researchers.

Wayne Kuznar

Dexrazoxane Has Long-term Cardioprotective Effects in Childhood ALL Survivors

TOP - Daily

Dexrazoxane provides long-term protection against against doxorubicin-induced heart damage in survivors of childhood high-risk acute lymphoblastic leukemia (ALL) and does not compromise oncologic efficacy, a new multicenter study indicates.

TOP - Daily

Discontinuation of imatinib therapy puts patients with advanced gastrointestinal stromal tumors (GIST) at high risk for rapid disease progression and is not recommended unless substantial toxicity develops, according to French researchers.

After nearly 3 years of follow up, 2-year progression-free survival was 80% in patients who remained on imatinib but only 16% in those whose treatment was stopped.

TOP - Daily

Regular consumption of three to four alcoholic drinks per week increases the risk of breast cancer recurrence and death from breast cancer, a study of breast cancer survivors suggests. Postmenopausal and overweight or obese women are at greatest risk.

TOP - Daily

Nearly 50% of patients with the most aggressive form of thyroid cancer had long-lasting responses to pazopanib in a phase 2 study by Mayo Clinic researchers.

TOP - Daily

A man’s level of prostate specific antigen (PSA) at age 60 predicts his lifetime risk of metastasis and death from prostate cancer, a study of Swedish men indicates.

The findings, published online September 14 in BMJ, could be useful in determining which men should be screened for prostate cancer after the age of 60 and which may not benefit substantially from continued screening.

TOP - Daily

In a case-control study, regular use of 75 mg/day of aspirin— lower than the standard 81-mg dose of baby aspirin—significantly reduced the risk of developing colorectal cancer (CRC). The effect was evident after 1 year and increased with longer use.

The findings of this large population-based study are applicable to the general population, not just high-risk patients, according to the authors.

August 2010 Vol 3, No 5

This past April, Albert Einstein Cancer Center was selected to join the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP), which, in the words of William J. Tester, MD, FACP, medical director of Einstein’s Cancer Center, offers “an opportunity to bring more resources to our patients.”

August 2010 Vol 3, No 5

CHICAGO—Several new agents elicited excitement for the treatment of women with advanced breast cancer, including a novel cytotoxic agent that is the first to improve survival as mono therapy in this challenging patient population.

In an international study, patients with metastatic breast cancer refractory to numerous treatments lived 2.5 months longer when treated with eribulin mesylate, a synthetic analog of the novel halichondrin B family, versus single agents alone.

Dying at Home Enhances Quality of Life

TOP - Daily

Patients with advanced cancer who die at home have greater quality of life (QOL) than patients who die in a hospital or intensive care unit. In addition, their caregivers experience less bereavement-related psychiatric illnesses, according to a study published online at the Journal of Clinical Oncology.

Articles

Page 276 of 288